IFN-1 Test
Commercial- Indications
- Systemic Lupus Erythematosus
Company intelligence / Profile preview
DxTerity develops and commercializes RNA-based diagnostic platforms focused on precision medicine for autoimmune diseases. Their at-home sample collection kits enable real-world genomics monitoring to improve disease management. The company’s lead programs include gene expression signatures such as Type I interferon modules relevant to SLE and other autoimmune conditions. They operate a CAP-accredited/CLIA-certified lab in California and have received FDA EUA authorization for a COVID PCR test. Ongoing clinical studies are validating new biomarkers and expanding their pipeline of precision diagnostics.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DxTerity.